N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 48

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H1 2018

Summary

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) pipeline Target constitutes close to 6 molecules. The latest report N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H1 2018, outlays comprehensive information on the N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - N-sulphoglucosamine sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III. The molecules developed by companies in Phase II, IND/CTA Filed and Preclinical stages are 4, 1 and 1 respectively. Report covers products from therapy areas Genetic Disorders which include indications Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ).

Furthermore, this report also reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1)

- The report reviews N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Overview
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
ArmaGen Inc
Laboratorios Del Dr Esteve SA
Lysogene SAS
Swedish Orphan Biovitrum AB
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Drug Profiles
ABO-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGT-184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYSSAF-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYSSAF-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOBI-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Discontinued Products
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Product Development Milestones
Featured News & Press Releases
May 18, 2018: Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
Apr 23, 2018: Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
Feb 08, 2018: Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
Feb 06, 2018: Lysogene gets PIP Green Light from European Medicines Agency on MPS IIIA Pivotal Study; Paving Way for Clinical Trial Application Approvals
Feb 01, 2018: Lysogene to Present Five Year Clinical Data in MPS IIIA at the 14th Annual WORLDSymposium
Jan 23, 2018: FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA
Nov 09, 2017: Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
Oct 11, 2017: Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
Oct 06, 2017: Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM's Cell & Gene Meeting on the Mesa
Oct 05, 2017: Lysogene to Host Key Opinion Leader Meeting on Gene Therapy for Patients with Sanfilippo Syndrome Type A in New York City
Sep 28, 2017: Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
Aug 17, 2017: Abeona Therapeutics Provides Update on ABO-102 at R&D Day on October 11, 2017
Aug 16, 2017: Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
Jul 05, 2017: FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA
May 30, 2017: Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Abeona Therapeutics Inc, H1 2018
Pipeline by ArmaGen Inc, H1 2018
Pipeline by Laboratorios Del Dr Esteve SA, H1 2018
Pipeline by Lysogene SAS, H1 2018
Pipeline by Swedish Orphan Biovitrum AB, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Anti-infective Ophthalmic Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 122
    Ophthalmic anti-infectives are anti-infectives contained in a product formulated especially to be instilled or applied in the eye or eyes. Ophthalmic anti-infectives include eyedrops, gels or ointments. Anti-infectives are drugs that can either kill an infectious agent or inhibit it from spreading. Anti-infectives include antibiotics and antibacterials, antifungals, antivirals and antiprotozoals. Scope of the Report: This report focuses on the Anti-infective Ophthal......
  • Global Cannabis Oil Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 124
    Cannabis oil is from the marijuana plant (cannabis indicas). The oil is extracted from the leaves of the cannabis plant. It contains high levels of THC. It is used for medicinal purposes and as a recreational drug. Cannabis oil reached considerable popularity when a man in Canada named Rick Simpson began distributing this concentrate, albeit illegally, as a medicine. Rick's oil (commonly known as "Rick Simpson oil") brought the long studied knowledge about the anti-tumor and various medi......
  • Global Darbepoetin Alfa Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 124
    Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and ......
  • Global Hemostasis and Tissue Sealing Agents Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 136
    Hemostasis is a process which causes bleeding to stop, meaning to keep blood within a damaged blood vessel (the opposite of hemostasis is hemorrhage). It is the first stage of wound healing. Tissue sealing agents are used during medical procedures to achieve hemostasis. They vary based on their mechanism of action, composition, ease of application, adherence to tissue, immunogenicity and cost. These agents permit rapid hemostasis, better Visualization of the surgical area, shorter operati......
  • Global Humira Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 121
    Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa. Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis. ......
  • Global Hypromellose Acetate Succinate Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 119
    Hypromellose acetate succinate is an enteric coating material which was first approved in Japan in 1987. As of January 2004, this product has been approved in Korea, several countries in Europe, and USA as well as in Japan. Scope of the Report: This report focuses on the Hypromellose Acetate Succinate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manuf......
  • Global IGY Polyclonal Antibodies Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 120
    Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is also found in high concentrations in chicken egg yolk. As with the other immunoglobulins, IgY is a class of proteins which are formed by the immune system in reaction to certain foreign substances, and specifically recognize them. IgY antibodies have a different structure from IgG, particularly in the Fc and hinge regions. The affinity maturation proces......
  • Global Platinum based Cancer Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 122
    Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. They are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, popular drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. Scope of the Report: This report focuses on the Platinum based Cancer Drug......
  • Global Hepatocyte Growth Factor Market Professional Survey Report 2018
    Published: 20-Aug-2018        Price: US 3500 Onwards        Pages: 104
    This report studies the global Hepatocyte Growth Factor market status and forecast, categorizes the global Hepatocyte Growth Factor market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs